Information on the expected shortage of the medicinal product ImmuCyst 81 mg powder for suspension for intravesicular use, BCG for immunotherapy
17.05.2012
Medoka d.o.o., the marketing authorisation holder for the medicinal product ImmuCyst 81 mg powder for suspension for intravesicular use, BCG for immunotherapy has notified the Agency for Medicinal Products and Medical Devices about the expected shortage of this medicine on the Croatian market. The product manufacturer, Sanofi Pasteur Limited (Toronto, Canada) has temporarily disrupted the supply of the product Immucyst, due to which a global shortage is expected.
The available dosages of the medicinal product ImmuCyst in Croatia are not affected by the aforementioned disruption. The marketing authorisation holder will inform about the expected shortage all the healthcare facilities where the product is used.
The public will be informed in due time about every new information on the availability of the product.
